Two Austin-based companies involved in medial research say they expect to raise millions of dollars with stock offerings this week.
What do small cap and micro cap investors look at? We thought you’d want to know what we discovered when we took a look back at Channelchek's most popular content of 2020.
And the winners are ... Genprex Inc. (Nasdaq: GNPX), a gene therapy company headquartered in the Texas capital, took the regional title of the year’s largest increase in share value.
An experimental gene therapy developed by Texas biotech Genprex will be paired with AstraZeneca’s Tagrisso and Merck & Co’s Keytruda – both leading their respective drug classes in the treatment of non-small cell lung cancer (NSCLC).
Genprex announced that quaratusugene ozeplasmid (Reqorsa) will be studied in two new trials, in which non-small cell lung cancer patients with specific molecular markers will receive its investigational drug combined with osimertinib (AstraZeneca's Tagrisso) or pembrolizumab (Merck's Keytruda).
Companies are optimizing nonviral delivery methods for commercial use
Austin startup a ripe M&A target for big pharma, one expert says
Inside the industry's quest for its next crowning achievement in oncology.
A UPMC Children’s Hospital of Pittsburgh researcher is crediting a new, supportive environment for entrepreneurs at the University of Pittsburgh for making it possible to license a technology that may one day cure diabetes.
Austin-based biotech firm Genprex is looking for more growth after raising about $25.5 million through two recent stock offerings.
Designed and Secured by Barsec